BioCentury
ARTICLE | Finance

Ansun’s China ambitions

How Chinese series A syndicate could help Ansun crack China’s antiviral market

May 18, 2018 8:06 PM UTC

The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market.

Sinopharm Healthcare Fund and Lilly Asia Ventures led the round, with participation from fellow new Chinese investors Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures and Joincap Investment. Ansun interim CEO Nancy Chang said undisclosed U.S.-based investors also participated. ...